IFNB1 and myeloid sarcoma: Further, in vitro analysis proposed IL-27 as a marker to identify responders to IFN-β treatment [6] as IL-27 secretion was increased from ex vivo isolated plasmacytoid dendritic cells (pDCs) from MS patients treated with IFN-β for 1 month [7].